-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on ImmunityBio, Maintains $12 Price Target

Benzinga·05/21/2026 10:10:38
Listen to the news
BTIG analyst Jeet Mukherjee reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $12 price target.